Marina Scop

Marina Scop


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MOMelissa Oliveira
Melissa Oliveira
EFEuclides José de Mendonça Filho
Euclides José de Mendonça Filho
ACAlicia Carissimi
Alicia Carissimi
LGLuciene Lima dos Santos Garay
Luciene Lima dos Santos Garay
MSMarina Scop
Marina Scop
MHMaria Paz Hidalgo
Maria Paz Hidalgo
Background: Recent studies with the mood rhythm instrument (MRhI) have shown that the presence of recurrent daily peaks in specific mood symptoms are significantly associated with increased risk of psychiatric disorders. Using a large sample collected in Brazil, Spain, and Canada, we aimed to analyze which MRhI items maintained good psychometric properties across cultures. As a secondary aim, we used network analysis to visualize the strength of the association between the MRhI items. Methods: Adults (n = 1275) between 18–60 years old from Spain (n = 458), Brazil (n = 415), and Canada (n = 401) completed the MRhI and the self-reporting questionnaire (SRQ-20). Psychometric analyses followed three steps: Factor analysis, item response theory, and network analysis. Results: The factor analysis indicated the retention of three factors that grouped the MRhI items into cognitive, somatic, and affective domains. The item response theory analysis suggested the exclusion of items that displayed a significant divergence in difficulty measures between countries. Finally, the network analysis revealed a structure where sleepiness plays a central role in connecting the three domains. These psychometric analyses enabled a psychometric-based refinement of the MRhI, where the 11 items with good properties across cultures were kept in a shorter, revised MRhI version (MRhI-r). Limitations: Participants were mainly university students and, as we did not conduct a formal clinical assessment, any potential correlations (beyond the validated SRQ) cannot be ascertained. Conclusions: The MRhI-r is a novel tool to investigate self-perceived rhythmicity of mood-related symptoms and behaviors, with good psychometric properties across multiple cultures.

26 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MSMarina Scop
Marina Scop
PFPamela C.L. Ferreira
Pamela C.L. Ferreira
BBBruna Bellaver
Bruna Bellaver
EREmma Ruppert
Emma Ruppert
HZHussein Zalzale
Hussein Zalzale
TPTharick A Pascoal
Tharick A Pascoal
Background: The Alzheimer's Association workgroup criteria (AA‐2024) suggest four biological stages based on PET imaging. However, the application of this framework may vary depending on the tau PET tracer used, and the distribution of clinical stages by biological stage may differ. Here, we aim to compare the diagnostic performance of the biological staging of Alzheimer Disease using two different tau PET tracers. Method: We analyzed 446 individuals and further stratified 167 Aβ‐positive participants from the HEAD study (Longitudinal multicenter head‐to‐head harmonization of tau PET tracers) that underwent both MK‐6240 and Flortaucipir (FTP) tau PET. Four clinical stages (normal, transitional, MCI, and dementia) were defined based on the AA‐2024 criteria. Within stage‐2 we assessed subgroups: subjective cognitive decline (SCD), subtle objective cognitive decline (SOCD), and mild behavioral impairment (MBI). Logistic and linear models corrected by age and sex tested association of groups with amyloid and tau pathology. The biological staging was performed using tracer‐specific thresholds for regional SUVR and testing two regions of interest schemes: (i) proposed by AA‐2024 and (ii) Braak stages (Figure 1). Cohen's weighted‐kappa (K) statistic measured clinical‐biological agreement. Positive predictive value (PPV) of an individual being clinically impaired (MCI or dementia) was calculated for each biological stage. Result: Clinical stages showed a progressively increased prevalence of Aβ‐positivity and higher entorhinal tau PET pathology from cognitively normal (CN) to SOCD, MCI, and dementia in both tracers. MBI and SCD transitional groups showed no increased Aβ or tau pathology compared to CN (Figure 2). For this reason, only SOCD was considered part of stage 2 for following analyses. All tested biological staging strategies showed moderate agreement (0.34‐0.59) with clinical stages using either tracers. The distribution of biological across clinical stages were similar for FTP and MK, with MK‐6240 showing lower PPV values in earlier stages than FTP (Table 1). Conclusion: Our results support that AA‐2024 biological and clinical stages show similar clinical‐biological concordance using either Flortaucipir or MK‐6240, although this can vary based on methods tested in the study. The MBI and SCD clinical subgroups showed no difference of pathological burden to clinical stage 1, while SOCD transitional stage showed higher burden compared to stage 1.